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ABSTRACT 
Objective: This study was designed to evaluate the effect of the methanol extract of M. foetida (MEMf) on high fat diet-induced obese male rats.  
Methods: Four groups (experimental groups) of 6 male Wistar rats each were fed with a high-fat diet (HFD) for 4 w and then treated with either 
distilled water (control group), MEMf (50 or 100 mg/kg) or the reference compound Atorvastatin (10 mg/kg) for 27days. The body weight was 
recorded every two days
Results: HFD induced an increase (P<0.05) in the body and liver weights and the relative abdominal fat pad of the animals in the experimental 
groups as compared to those in the normal diet group. Also, HFD in the experimental groups reduced (P<0.05) superoxide dismutase and catalase 
activities, glutathione levels and increased lipid peroxidation in the liver, heart and kidney as well as altered lipid profile (increased serum 
triglycerides, total cholesterol, low-density lipoproteins (LDL-C), very low-density lipoproteins (VLDL-C), decreased high-density lipoproteins 
(HDL-C), increased atherogenic index and coronary risk index), when compared to the normal diet animals. All altered parameters were 
subsequently normalized when obese rats received either MEMf (50 or100 mg/kg) or the reference drug 
. A fifth group made up of rats (normal diet group) not subjected to a HFD was used as a negative control for the HFD obese 
rats. The Lee index, lipid profile and antioxidant parameters were assessed using animal body weight and biochemical methods, respectively. 
Conclusion: This study demonstrates the potential of MEMf to normalize hyperlipidemia, oxidative stress and animal visceral organ weights 
increased by HFD in rats. Thus, M. foetida is an interesting medicinal plant that could be exploited as sources of anti-obesity agents. 
Atorvastatin. 
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INTRODUCTION 
Obesity is a condition in which body fat accumulates to the extent of 
causing an adverse effect on health, leading to increased health 
problems and even reduced life expectations. The prevalence of 
obesity is increasing globally, with 1.9 billion adults overweight in 
2016, and 650 million obese [1]. This prevalence varies between 
countries with the lowest being Japan (3.7%) and the highest being 
the United States with
Obesity results from complex interactions of genetic, behavioral and 
environmental factors correlating with lifestyles, economic and 
social status [5]. It can only occur when the energy value of food 
eaten exceeds energy expended. This is known as “a positive energy 
balance”, a situation whereby excess intake of energy in the form of 
food will inevitably appear as deposits of fat [6]. Regarding food 
consumption, study has suggested the existence of a rural-urban 
trend towards an increase lipid content of the diet, particularly in 
developing countries such as Cameroon [7]. Obesity facilitates the 
development of other metabolic disorders such as diabetes, 
hypertension and cardiovascular diseases [5]. Obesity also induces 
dysregulation of endocrine secretion of adipocytokines or 
adipokines characterized by chronic low-grade inflammation with 
increase oxidative stress. The latter damages cellular structures 
leading to the development of obesity-related complications 
[8].
 38.2% [2]. Sub-Saharan Africa countries are 
also facing the increasing burden of overweight and obesity among 
their populations. For instance, from 1975 to 2014 the trends of 
obesity in sub-Saharan Africa have increased by more than 7% in 
both genders [3]. For Cameroon, in 2019, the prevalence of 
overweight was estimated at 26.0% and the overall prevalence of 
obesity was 15.1% [4]. 
 
Medicinal plants, thanks to their phytonutrients and their uses for 
millenaries may constitute good sources of anti-obesity drugs [13]. 
Herbal remedies are gaining more interests across the globe due to 
their ready availability, low cost and the common belief that they are 
natural and safer as compared to synthetic drugs. However, 
adequate scientific evidences on medicinal plants are needed for 
their optimal and rational usage. Hence, more detailed herbal 
studies are needed on suitable animal models in the search for novel 
anti-obesity agents. Previous reports showed the anti-obesity 
activity of some medicinal plants [14]. M. foetida is a medicinal plant, 
widely distributed in tropical Africa and has been used in folk 
medicine to control diabetes and hypertension which are the 
common complications in obesity. This plant is also used for the 
treatment of malaria and stomachache [15, 16]. M. foetida is rich in 
antioxidants molecules phenolics, flavonoids and vitamin C, and has 
shown significant antioxidant activity [17]. 
Different measures such as a change in diet, increased physical 
activity, use of anti-obesity drugs, dietary supplements, and even 
surgery are proposed for management of obesity [9, 10]. However, 
some approved anti-obesity drugs have been withdrawn because of 
their side effects. Surgery is not only costly but can also lead to 
serious adverse outcomes [11, 12]. It is therefore vital to look for 
new therapeutic options for better management of obesity.  
Therefore, 
MATERIALS AND METHODS 
M. foetida 
could display beneficial effects in the management of obesity and its 
related complications. This study therefore aimed at investigating 
the effects of the methanol extract of M. foetida in high fat induced-
obese male Wistar rats. 
Collection of M. foetida and preparation of the methanol extract 
The whole M. foetida plant (roots, stem and leaves) was harvested in 
Bambili village (Mezam division, Cameroon) in July 2018 and 
identified by a botanist of the Faculty of Science of the University of 
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Bamenda. A specimen was preserved at the Cameroonian National 
Herbarium (HNC) under the voucher number 33420 HNC. 
The plant was cleaned, dried at room temperature, chopped and 
finely ground. Four hundred grams of the dry matter from the whole 
plant were macerated into 2 L of methanol and allowed for 48 h with 
the mixture being swirled every 4 h. The supernatant was collected 
and filtered using whatman N °1 filter paper. The solvent was 
evaporated using a rotary evaporator under reduced pressure at 65 




Adult albino male Wistar rats were obtained from the animal house of 
the Department of Biochemistry (Faculty of Science, University of 
Bamenda, Cameroon). They were raised under standard conditions of 
temperature, humidity and a natural light/dark cycle. They 
Reagents and kits 
had free 
access to food and drinking water during the experimental period. The 
animals were handled according to ethical guidelines of the Cameroon 
National Veterinary Laboratory as reference by the approval and 
health control No 001/17 CCS/MINEPIA/RD-NW/DD-ME/SSV. 
Atorvastatin calcium tablets were purchased from Ajanta pharma 
limited, Kandivli (Mumbai, India). Total cholesterol, triglycerides 
and high density lipoprotein cholesterol (HDL-C) kits were 
purchased from Chronolab Systems (Barcelona, Spain). 
Trichloroacetic acid (TCA) and thiobarbituric acid (TBA) were 
obtained from Sigma Aldrich (France), while 2,2-dithio-5,50-
dibenzoic acid was gotten from Burgoynes and Co. (Mumbai, India). 
Other chemicals were of analytical grade. 
Experimental design 
Aside the normal diet control group (fed on a normal diet composed 
of 70% corn flour, 10% palm oil, 10% soya beans flour, 8% fish 
powder, 1% bone powder and 1% vitamin), the other rats 
(experimental groups) were given high fat diet (composed of 50% 
corn flour, 30% palm oil, 10% soya beans flour, 8% fish powder, 1% 
bone powder and 1% vitamin) daily for 28 d. The obese status of the 
animals was confirmed with Lee’s index ≥ 300 [18, 19]. Obese rats 
were partitioned into four groups of six animals each, orally treated 
for 27 d with either distilled water (10 ml/kg), 50 or 100 mg/kg of 
MEMf, or 10 mg/kg of Atorvastatin (the reference compound). The 
choice of doses of MEMf and Atorvastatin was based on previous 
studies [19, 20]. The group of normal diet control rats was left 
untreated, and body weights of all animals were recorded every two 
days. 
At the end of the treatment, the animals were fasted overnight, then 
anesthetized using diazepam (10 mg/kg) and sacrificed. Capillary 
blood was collected and serum prepared for subsequent biochemical 
analyses. The organs liver, heart, kidney as well as abdominal fat 
pads were dissected out and weighed. Homogenates (20% w/v, in 
phosphate buffer (pH 7.4, 50 mmol)) were prepared from the liver, 
heart and kidney and used for the assessment of antioxidant 
parameters. 
Assessment of serum lipid profile 
Lipid profile was estimated in serum samples. To this end, 
parameters such as triglyceride (TG), total cholesterol (TC) and 
high-density lipoprotein (HDL-C) concentrations were quantified 
using Chrono Lab kits according to the manufacturer’s instructions. 
Low-density lipoproteins (LD-CL), very low-density lipoproteins 
(VLDL-C), atherogenic index (AI) and coronary risk index (CRI) were 





Evaluation of antioxidant parameters 
Superoxide Dismutase (SOD) and catalase activity were assayed 
according to the method of Misra and Fridovich [22]. Reduced 
glutathione was determined using Ellman reagent [23]. 
Thiobarbituric acid reacting substances (TBARS) level was assessed 
by the method of Wilbur et al. [24]. All antioxidant parameters were 
corrected using protein levels in the respective organ homogenates, 
which were determined according to Gornall et al. [25]. 
Statistical analysis 
The statistical package minitab version 18.1 was used for the 
analyses. Data were analyzed statistically using one-way analysis of 
variance (ANOVA), followed by Tukey’s pair-wise comparison. 
Values were considered as statistically significant at p<0.05. 
RESULTS 
Effect of MEMf on the animal body weight and lee index 
Treatment with 50 mg/kg of MEMf or 10 mg/kg Atorvastatin 
reduced the body weight of HFD obese rats from day 15, as 
compared with the obese untreated group (fig. 1). However, the 
higher dose of the plant extract did not show any effect on the 
animal body weight. 
As shown in table 1, all doses of the plant extract and the reference 
compound Atorvastatin significantly (P<0.05) reduced the Lee index 
as compared to the untreated HFD animals. However, none of the 
treatments totally normalize the Lee index with respect to the 
normal diet control group. 
 
 
Fig. 1: Variation in the body weights of obese rats with different treatments, values represent mean±SD of 6 animals per group. Atvn: 
Atorvastatin, HFD: high-fat diet, MEMf: methanol extract of M. foetida 
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Table 1: Lee index of animals during the experimentation 
Groups Lee index at beginning of the treatment Lee index at day 27 
Normal control 275.95±2.55 277.81±3.24a 
HFD+DW (10 ml/kg) 323.42±8.26 331.61±7.11
HFD+MEMf (50 mg/kg) 
c 
319.47±2.10 305.04±3.50
HFD+MEMf (100 mg/kg) 
b 
321.93±5.32 310.42±4.85
HFD+Atorvastatin (10 mg/kg) 
b 
320.32±8.46 302.82±4.68b 
Values represent mean±SD of 6 animals per group. Values not sharing a common letter differ significantly with the normal control and with each 
other (P<0.05, Tukey’s pair-wise comparison). DW: distilled water, HFD: high-fat diet, MEMf: methanol extract of M. foetida. 
 
Effect of MEMf on animal organ weights 
HFD significantly increased (P<0.05) the liver and fat pad 
weights of the obese control animals when compared to the 
normal control group (table 2). The MEMf or Atorvastatin 
significantly corrected the animal liver weight while only the 
reference molecule normalized the fat pad weight as compared 
to control normal rats. The other organs (kidney and heart) were 
affected neither by the HFD, plant extract, nor the reference 
compound Atorvastatin. 
 
Table 2: Effect of MEMf on the relative fat pad, liver, heart and kidney weights 
Organ weight (g/100 g BW) Normal control Control HFD MEMf (50 mg/kg) MEMf (100 mg/kg) Atvn(10 mg/kg) 
Abdominal fat pad 2.53±0.47 3.51±0.54b 2.82±0.46a 2.92±0.43ab 2.41±0.30ab b 
Liver 2.35±0.17 3.09±0.30b 2.60±0.14a 2.646±0.14b 2.38±0.13b 
Kidney 
b 
0.61±0.04 0.63±0.07a 0.59±0.03a 0.62±0.06a 0.55±0.04a 
Heart 
a 
0.37±0.03 0.42±0.08a 0.39±0.03a 0.39±0.01a 0.35±0.01a a 
Values represent mean±SD of 6 animals per group. Values not sharing a common letter differ significantly with the normal control and with each 
other (P<0.05, Tukey’s pair-wise comparison). Atvn: Atorvastatin, HFD: high-fat diet, MEMf: methanol extract of M. foetida. 
 
Effect of MEMf on serum lipid profile 
Serum lipid profile of the rats after treatment with MEMf or 
Atorvastatin is shown in table 3. The HFD significantly (P<0.05) 
increased serum TC, TG, LDL-C and VLDL-C concentrations as well as 
AI and CRI while it reduced (P<0.05) serum HDL-C levels. The 
treatment of rats with both doses of MEMf or the reference compound 
Atorvastatin normalized these parameters as compared with the 
normal control animals. The effect of the plant extract on animal lipid 
profile was comparable to that of the reference compound. 
  
Table 3: Serum lipid profile of HFD-induced obese Wistar rats upon different treatments 
Lipid profile  Normal control Control HFD MEMf (50 mg/kg) MEMf (100 mg/kg) Atvn(10 mg/kg) 
TC (mg/dl) 81.81±4.49 125.82±2.77bc 70.17±10.52a 90.21±10.53c 86.48±7.82b b 
TG (mg/dl) 66.33±8.62 84.64±16.63ab 50.27±9.10a 76.48±12.42b 73.21±2.99a 
LDL-C (mg/dl) 
a 
38.81±5.77 85.59±7.20b 40.64±5.03a 52.66±7.80b 45.97±7.15b 
HDL-C (mg/dl) 
b 
30.20±2.93 18.66±1.71a 24.23±3.21d 22.01±2.00bc 26.36±2.45cd 
VLDL-C (mg/dl) 
b 
12.90±2.48 21.34±4.07b 11.38±0.61a 15.29±2.48b 14.64±0.59b 
AI 
b 
1.34±0.250 5.50±1.06c 2.15±0.38a 2.65±0.43bc 2.09±0.29b 
CRI 
bc 
2.48±0.13 6.21±0.37b 2.64±0.40a 3.11±0.50b 2.51±0.45b b 
Values represent mean±SD of 6 animals per group. Values not sharing a common letter differ significantly with the normal control and with each 
other (P<0.05, Tukey’s pair-wise comparison). AI: atherogenic index, Atvn: Atorvastatin, CRI: coronary risk index, HFD: high-fat diet, HDL-C: high-
density lipoproteins, LDL-C: low-density lipoproteins, MEMf: methanol extract of M. foetida, TC: total cholesterol, TG: triglyceride, VLDL-C: very-low-
density lipoproteins. 
 
Table 4: Antioxidant parameters of rat organs upon different treatments 
Organ  Antioxidant parameters Normal 
control 
Control HFD MEMf (50 mg/kg) MEMf (100 
mg/kg) 
Atvn(10 mg/kg) 
Heart SOD (IU/mg of proteins) 60.92±0.28 15.54±0.59a 44.76±4.70e 30.94±4.50b 25.10±2.23c d 
CAT (IU/mg of proteins) 66.39±9.04 50.38±8.32a 60.99±7.08b 53.33±5.85ab 54.18±7.24b 
GSH (mmol/mg proteins) 
b 
2.15±0.11 1.43±0.11a 1.05±0.20c 1.92±0.37bc 1.50±0.04ab 
Liver 
c 
SOD (IU/mg of proteins) 33.13±1.88 25.94±3.96a 31.69±1.93b 30.03±4.94a 29.45±4.28ab 
CAT (IU/mg of proteins) 
ab 
111.91±22.23 85.63±6.82bc 152.48±22.50c` 101.73±2.89a 129.39±22.90bc 
GSH (mmol/mg proteins) 
ab 
3.12±0.52 1.74±0.31a 2.02±0.37c 2.60±0.36bc 2.30±0.40ab 
TBARS (nmol/mg proteins) 
bc 
3.10±0.55 7.17±1.36b 4.35±0.77a 4.01±0.63b 3.57±0.56b 
Kidney 
b 
SOD (IU/mg of proteins) 48.06±6.04 31.57±2.74a 40.92±5.38c 34.79±1.49b 36.36±4.98bc 
CAT (IU/mg of proteins) 
bc 
85.66±9.27 55.51±5. 99a 70.54±8.22c 54.26±8.10b 58.16±9.80c 
GSH (mmol/mg proteins) 
c 
2.56±0.45 2.15±0.31ab 2.32±0.30bc 2.79±0.35ab 1.75±0.16a 
TBARS (nmol/mg proteins) 
c 
0.27±0.05 0.50±0.02c 0.40±0.07a 0.42±0.06b 0.29±0.05ab c 
Values represent mean±SD of 6 animals per group. Values not sharing a common letter differ significantly with the normal control and with 
eachother (P<0.05, Tukey’s pair wise comparison). Atvn: Atorvastatin, CAT: catalase, GSH: glutathione, HFD: high-fat diet, MEMf: methanol extract of 
M. foetida, SOD: superoxide dismutase, TBARS: thiobarbituric acid reacting substances. 
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Effect of MEMf on antioxidant parameters 
In general, HFD significantly reduced (P<0.05) antioxidant enzyme 
activities and glutathione levels while it increased TBARS levels 
(table 4). The plant extract or Atorvastatin alleviated HFD effect on 
SOD activity. The lower dose of the plant extract (50 mg/kg) showed 
the most significant mitigating effect on this enzyme activity. The 
plant extract and the reference compound seemed to exhibit more 
significant antioxidant effect noted on liver than other organs. On 
catalase activity, the decreasing effect induced by the HFD in obese 
rats was normalized by MEMf, notably the dose 50 mg/kg. 
Atorvastatin displayed a significant alleviating effect on the catalase 
activity only on liver homogenate. The lower dose of MEMf (50 
mg/kg) and Atorvastatin also induced restoration of the glutathione 
levels depleted, and corrected increased TBARS levels. 
DISCUSSION 
Exposure of rats to HFD increased their body weights; a factor 
known as a hallmark of obesity, confirmed by the Lee index ≥300. 
The increase in body weight is attributed to the rich caloric diet and 
fat accumulation in various parts of the body, leading to excessive 
growth of adipose tissue [26]. The body weight of the obese animals 
was significantly reduced by MEMf at the dose 50 mg/kg and 
Atorvastatin (10 mg/kg). Similarly, studies carried out by Athesh 
and Jothi [27] and Kaveripakam et al. [14] revealed a decrease in 
body and organ weight in HFD-induced obese rats and mice, after 
administration of Acorus calamus and Stereospermum suaveolens, 
respectively. 
Cholesterol is an important structural component of the cell, in 
addition, it is the precursor for the synthesis of steroid hormones. 
Nonetheless, hyperlipidemia occurs when there is an abnormal 
increase in the total plasma concentrations of TC, TG and LDL-C with 
a reduction of HDL-C level. Hyperlipidemia forms the basis of the 
development of coronary heart diseases, which by themselves, 
constitute a major health problem of great concern [21]. In this 
study, rats that received only HFD registered a significant increase in 
serum TC, TG, LDL-C and VLDL-C levels, while HDL-C levels 
decreased. This may be due to an increase in both de-novo TG and 
cholesterol synthesis, and intestinal lipid uptake from the fat 
enriched diet [14]. As the reference drug Atorvastatin, which 
exhibits similar effects with MEMf in this experiment, has been 
shown to inhibit 3 hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase [6], the normalization of the lipid profile by the plant 
extract may be due to its ability to lower lipogenesis through 
inhibition of HMG-CoA reductase. Substances from the plant extract 
may also enhance lipolysis, suppress appetite and reduce lipid 
absorption [14]. The observed improvement of the lipid profile 
corroborates the findings of Kaveripakam et al. [14] who observed 
that 40 d administration of Stereospermum suaveolens in HFD rats 
decreased the serum concentrations of TC, TG, LDL-C and increased 
HDL-C levels. 
In animal and human studies, obesity is connected with a decrease 
in tissue or plasma antioxidant capacity characterized by low levels 
of antioxidant enzymes predominantly catalase, glutathione 
peroxidase and glutathione reductase. Antioxidants have been 
reported to play an important role in the enhancement of 
antioxidant defence mechanisms in the obese rodent model [30]. 
Moreover, antioxidants have been shown to be the natural protector 
against lipid peroxidation. They are important scavengers of 
superoxide ions and hydrogen peroxide thus preventing hydroxyl 
radicals generation and protecting cellular constituents from 
oxidative damage [17, 31]. HFD has been shown to increase free 
radical production in vivo, which results in elevated TBARS levels 
[30]. The altered antioxidant system in HFD-induced obese rats, 
characterized by reduction of SOD and CAT activities and glutathion 
levels as well as increased TBARS could be due to the accumulation 
of superoxide radicals and hydrogen peroxide [30]. Interestingly, 
this was normalized by MEMf, probably because of its richness in 
antioxidant molecules such as polyphenols, flavonoids and vitamin C 
[17]. This is in accordance with the findings of Kim et al. [32] who 
reported a similar trend with red ginseng alleviating the reduction 
in SOD activity in HFD-exposed rats. Similarly, Kumar et al. [33] 
observed a reduction in TBARS levels upon administration of 
Gymnema sylvestre ethanol extract to HFD-induced obese diabetic 
rats. The hypolipidemic effect of MEMf could therefore be due to its 
content in antioxidants, as the reference drug Atorvastatin also 
exhibits antioxidant activity [6, 17, 34, 35]. 
Similarly, Joshi et al. [28] demonstrated the benefit of a 
medicinal herb, Cinnamomum verum, through a decrease of total 
cholesterol, triglycerides, phospholipids, LDL-C, VLDL-C and AI in 
New Zealand white male rabbits. A number of lipid parameters have 
been employed in predicting risk of coronary atherosclerosis and 
cardiovascular diseases. On a general note, recent data have shown 
that AI and CRI are more accurate predictors of cardiovascular risk 
than traditional lipid parameters [29]. Atherogenic dyslipidemia, 
characterized by a combination of increased TG, LDL-C and AI levels 
and decreased HDL-C level, was observed in the HFD control 
animals. This confirms that HFD could predispose to atherosclerosis 
and consequently to cardiovascular diseases [21]. When the HFD-fed 
rats were administered MEMf, this resulted into a profound 
reduction in the atherogenic and coronary risk indices and thereby 
further supporting the hypolipidemic effect of MEMf.  
Both doses of MEMf all showed interesting pharmacological effects 
in obese rats. However, the smaller dose of MEMf, 50 mg/kg seemed 
to be more effective than 100 mg/kg, precisely on animal body 
weight, TC, TG, LDL-C and AI. The higher anti-obesity effect at the 
lower dose of the MEMf showed a certain saturating activity of the 
active ingredient(s) of M. foetida between 50 and 100 mg/kg. 
Inconsistent dose-response effect was equally reported with the 
Bauhinia purpurea extract on biomarker such as body weight, lean 
mass, total free fat and leptin levels in high caloric diet-induced 
obese male rats [36]. More attention could be laid on the dose 50 
mg/kg of MEMf in future studies.  
CONCLUSION 
The findings from this study support the ability of MEMf to 
normalize hyperlipidemia, oxidative stress and increased visceral 
organ weights induced by HFD in rats. Therefore, M. foetida is an 
interesting medicinal plant that could be exploited as a source of 
anti-obesity agents. 
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